PNC-28
Modify Date: 2025-08-26 12:08:15
PNC-28 structure
|
Common Name | PNC-28 | ||
|---|---|---|---|---|
| CAS Number | 392661-17-5 | Molecular Weight | 3509.13 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C164H255N47O37S | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of PNC-28PNC-28 is a peptide from the mdm-2-binding domain (residues 17–26) of the p53 protein which contains a membrane crossing-penetratin sequence. PNC-28 can be used for pancreatic cancer research[1][2]. |
| Name | PNC-28 |
|---|
| Description | PNC-28 is a peptide from the mdm-2-binding domain (residues 17–26) of the p53 protein which contains a membrane crossing-penetratin sequence. PNC-28 can be used for pancreatic cancer research[1][2]. |
|---|---|
| Related Catalog | |
| In Vitro | PNC-28 (0-0.5 mg/mL) blocks growth of a lethal human pancreatic cancer cell line[2]. Cell Proliferation Assay[2] Cell Line: MiaPaCa-2 human pancreatic carcinoma cells Concentration: 0.1, 0.3, and 0.5 mg/mL Incubation Time: daily Result: Showed dependent induction of tumor cell death starting at 0.1 mg/ml. |
| In Vivo | PNC-28 (2 mg/mouse, SC or IP, for 14 days) blocks the growth of BMRPA1. Tuc3 cells in vivo[1]. PNC-28 (1-20 mg/mouse, SC, for 14 days) inhibits BMRPA1. Tuc3 tumor growth especially if delivered directly to the tumor [1]. Animal Model: Athymic Nu/Nu mice (7–8 weeks, 22–24 g, injected i.p. with BMRPA1.Tuc3 cells)[1] Dosage: 2 mg/mouse Administration: Implanted s.c. or i.p., with 14 days mini-osmotic pumps releasing PNC-28 at a rate of 0.25 μl/hr Result: No ascites was seen in the PNC-28-treated animals. strongly effective in inhibiting this particular tumor. Animal Model: Athymic Nu/Nu mice (7–8 weeks, 22–24 g, injected i.p. with BMRPA1.Tuc3 cells)[1] Dosage: 1 mg/mouse, 10 mg/mouse and 20 mg/mouse Administration: When the tumors reached sizes from 40 to 260 mg/mouse, mini-osmotic pumps were implanted s.c. that released, over a period of 14 days Result: Resulted in a significant level of tumor growth inhibition in a dose-related manner. |
| Molecular Formula | C164H255N47O37S |
|---|---|
| Molecular Weight | 3509.13 |
| InChIKey | OLBRWDOLLRHNOA-VSMYOHOGSA-N |
| SMILES | CSCCC(NC(=O)C(CCCCN)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(CCCCN)NC(=O)C(CCCCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCCCN)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(CC(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)C(N)CCC(=O)O)C(C)O)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCNC(=N)N)C(=O)NC(CC(N)=O)C(=O)NC(CCC(N)=O)C(=O)NC(Cc1ccccc1)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CCC(N)=O)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)O)C(C)C)C(C)C |